Pomanda estimates the enterprise value of TISSUE & CELL TECHNOLOGIES LIMITED at £1.6m based on a Turnover of £4m and 0.41x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of TISSUE & CELL TECHNOLOGIES LIMITED at £0 based on an EBITDA of £-1.2m and a 3.1x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of TISSUE & CELL TECHNOLOGIES LIMITED at £0 based on Net Assets of £-2.6m and 2.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Tissue & Cell Technologies LimitedOverview
Tissue & Cell Technologies Limited is a live company located in london, N20 0RA with a Companies House number of 12015631. It operates in the other human health activities sector, SIC Code 86900. Founded in May 2019, it's largest shareholder is
future med fund 888 pte ltd
with a 99% stake. Tissue & Cell Technologies Limited is a young,
small sized company, Pomanda has estimated its turnover at
£4m with
rapid
growth in recent years.
Pomanda's financial health check has awarded Tissue & Cell Technologies Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
Health Rating3out of 5
4 Strong
1 Regular
6 Weak
Size
annual sales of £4m, make it larger than the average company (£666.2k)
£4m - Tissue & Cell Technologies Limited
£666.2k - Industry AVG
Growth
3 year (CAGR) sales growth of 183%, show it is growing at a faster rate (5.9%)
183% - Tissue & Cell Technologies Limited
5.9% - Industry AVG
Production
with a gross margin of 21.9%, this company has a higher cost of product (38.2%)
21.9% - Tissue & Cell Technologies Limited
38.2% - Industry AVG
Profitability
an operating margin of -29.6% make it less profitable than the average company (5.7%)
-29.6% - Tissue & Cell Technologies Limited
5.7% - Industry AVG
Employees
with 12 employees, this is below the industry average (17)
12 - Tissue & Cell Technologies Limited
17 - Industry AVG
Pay Structure
on an average salary of £25.9k, the company has an equivalent pay structure (£25.9k)
£25.9k - Tissue & Cell Technologies Limited
£25.9k - Industry AVG
Efficiency
resulting in sales per employee of £329.6k, this is more efficient (£48.1k)
£329.6k - Tissue & Cell Technologies Limited
£48.1k - Industry AVG
Debtor Days
it gets paid by customers after 34 days, this is later than average (23 days)
34 days - Tissue & Cell Technologies Limited
23 days - Industry AVG
Creditor Days
its suppliers are paid after 389 days, this is slower than average (18 days)
389 days - Tissue & Cell Technologies Limited
18 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Tissue & Cell Technologies Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (111 weeks)
0 weeks - Tissue & Cell Technologies Limited
111 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 495.3%, this is a higher level of debt than the average (26.6%)
495.3% - Tissue & Cell Technologies Limited
26.6% - Industry AVG
TISSUE & CELL TECHNOLOGIES LIMITED financials
EXPORT
Tissue & Cell Technologies Limited's latest turnover from September 2023 is estimated at £4 million and the company has net assets of -£2.6 million. According to their latest financial statements, Tissue & Cell Technologies Limited has 12 employees and maintains cash reserves of £34.2 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Turnover
3,954,846
2,975,155
197,968
174,307
Other Income Or Grants
Cost Of Sales
3,087,456
2,332,211
158,226
137,092
Gross Profit
867,390
642,944
39,742
37,214
Admin Expenses
2,038,025
1,244,998
433,886
611,836
Operating Profit
-1,170,635
-602,054
-394,144
-574,622
Interest Payable
1,925
2,948
1,525
Interest Receivable
1,570
793
44
22
Pre-Tax Profit
-1,169,065
-603,186
-397,048
-576,125
Tax
Profit After Tax
-1,169,065
-603,186
-397,048
-576,125
Dividends Paid
Retained Profit
-1,169,065
-603,186
-397,048
-576,125
Employee Costs
310,300
292,954
211,168
183,747
Number Of Employees
12
12
9
8
EBITDA*
-1,161,315
-597,657
-390,172
-574,444
* Earnings Before Interest, Tax, Depreciation and Amortisation
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Tangible Assets
5,696
13,007
15,123
10,786
Intangible Assets
1,064
1,241
1,419
1,597
Investments & Other
249,505
249,505
126,312
Debtors (Due After 1 year)
Total Fixed Assets
256,265
263,753
142,854
12,383
Stock & work in progress
Trade Debtors
378,769
376,357
17,719
3,467
Group Debtors
Misc Debtors
269,614
161,571
Cash
34,232
25,590
44,934
43,988
misc current assets
total current assets
413,001
401,947
332,267
209,026
total assets
669,266
665,700
475,121
221,409
Bank overdraft
Bank loan
10,812
3,334
Trade Creditors
3,298,023
2,115,392
24,251
46,222
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
1,214,876
538,812
total current liabilities
3,298,023
2,115,392
1,249,939
588,368
loans
35,855
46,666
hp & lease commitments
Accruals and Deferred Income
other liabilities
16,667
26,667
provisions
total long term liabilities
16,667
26,667
35,855
46,666
total liabilities
3,314,690
2,142,059
1,285,794
635,034
net assets
-2,645,424
-1,476,359
-810,673
-413,625
total shareholders funds
-2,645,424
-1,476,359
-810,673
-413,625
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Operating Activities
Operating Profit
-1,170,635
-602,054
-394,144
-574,622
Depreciation
9,143
4,219
3,794
Amortisation
177
178
178
178
Tax
Stock
Debtors
2,412
89,024
122,295
165,038
Creditors
1,182,631
2,091,141
-21,971
46,222
Accruals and Deferred Income
-1,214,876
676,064
538,812
Deferred Taxes & Provisions
Cash flow from operations
18,904
189,584
141,626
-154,448
Investing Activities
capital expenditure
-1,832
-2,103
-8,131
-12,561
Change in Investments
123,193
126,312
cash flow from investments
-1,832
-125,296
-134,443
-12,561
Financing Activities
Bank loans
-10,812
7,478
3,334
Group/Directors Accounts
Other Short Term Loans
Long term loans
-35,855
-10,811
46,666
Hire Purchase and Lease Commitments
other long term liabilities
-10,000
26,667
share issue
-62,500
162,500
interest
1,570
-1,132
-2,904
-1,503
cash flow from financing
-8,430
-83,632
-6,237
210,997
cash and cash equivalents
cash
8,642
-19,344
946
43,988
overdraft
change in cash
8,642
-19,344
946
43,988
tissue & cell technologies limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for tissue & cell technologies limited. Get real-time insights into tissue & cell technologies limited's credit score, group structure and payment trends.
Perform a competitor analysis for tissue & cell technologies limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in N20 area or any other competitors across 12 key performance metrics.
tissue & cell technologies limited Ownership
TISSUE & CELL TECHNOLOGIES LIMITED group structure
Tissue & Cell Technologies Limited has no subsidiary companies.
Ultimate parent company
TISSUE & CELL TECHNOLOGIES LIMITED
12015631
TISSUE & CELL TECHNOLOGIES LIMITED Shareholders
The largest shareholders in Tissue & Cell Technologies Limited include Future Med Fund 888 Pte Ltd and Alexander John Scott-Barrett.
future med fund 888 pte ltd
99.01%
alexander john scott-barrett
0.99%
tissue & cell technologies limited directors
Tissue & Cell Technologies Limited currently has 3 directors.
The longest serving directors include
Mr Antony Rabar (May 2019) and
Mr Antony Rabar (May 2019).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to tissue & cell technologies limited.
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for TISSUE & CELL TECHNOLOGIES LIMITED. This can take several minutes, an email will notify you when this has completed.
tissue & cell technologies limitedCompanies House Filings - See Documents
